Introduction
Chronic migraine (CM) is a debilitating neurological disorder with a prevalence of 0.5% to 5% in the general population(1). It is associated with significant negative impact on quality of life (QOL) and mental health (2). Monoclonal antibodies targeting the CGRP pathway have been shown to be effective in episodic and chronic migraine. These molecular treatments work by binding either with the CGRP receptor or with the CGRP ligand(3). Raynaud’s phenomenon (RP) is characterized by brief reduction of blood flow to the extremities due to vasoconstriction(4). The relationship of RP and migraine is previously documented. Zahavi et al. reported RP in association with migraine in 26% (29/111) of patients (4). RP secondary to administration of migraine specific therapies, such as CGRP monoclonal antibodies, has been recently reported in a few cases.